Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bevacizumab-based Chemotherapy Tailored to the Pharmacokinetics of Bevacizumab in First-line Treatment of Unresectable Metastatic Colorectal Cancer: a Randomized, Multicenter, Double-blind Phase 3 Study

NCT06642844 is registered in ClinicalTrials.gov with University Hospital, Tours as lead sponsor.

NCT NCT06642844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06642844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bevacizumab-based Chemotherapy Tailored to the Pharmacokinetics of Bevacizumab in First-line Treatment of Unresectable Metastatic Colorectal Cancer: a Randomized, Multicenter, Double-blind Phase 3 Study
Lead sponsor
University Hospital, Tours
Phase
Phase 3
Overall status
Recruiting
Start date
March 4, 2025
Completion date
March 4, 2029
Enrollment
244 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable metastatic colorectal cancer